"NAN is beginning to make significant commercial progress with its probe sterilisation technology in hospital and related public health sites. After achieving 30 per cent market penetration in Australia, it has reported a 75 per cent increase in third quarter cash receipts, which lowered operating cash burn for the quarter to $500,000. NAN announced a new non-exclusive distributor for the UK, and its distribution agreement with GE in the US is now delivering significant orders. NAN’s trophon unit offers solid technology and few competitors."
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)